DILIC
ALNY icon

Dai-ichi Life Insurance Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Dai-ichi Life Insurance Company’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.96M Sell
5,930
-325
-5% -$111K 0.06% 256
2025
Q4 		$2.49M Buy
6,255
+800
+15% +$354K 0.06% 237
2025
Q3 		$2.49M Buy
5,455
+2,000
+58% +$814K 0.06% 242
2025
Q2 		$1.13M Buy
3,455
+2,500
+262% +$692K 0.03% 343
2025
Q1 		$258K Hold
955
– – 0.01% 474
2024
Q4 		$225K Hold
955
– – 0.01% 476
2024
Q3 		$263K Sell
955
-122
-11% -$31.8K 0.01% 475
2024
Q2 		$262K Buy
+1,077
New +$170K 0.01% 437
2023
Q4 		– Sell
-7,100
Closed -$1.26M – 463
2023
Q3 		$1.26M Buy
7,100
+504
+8% +$96.2K 0.03% 344
2023
Q2 		$1.25M Sell
6,596
-383
-5% -$75.9K 0.03% 351
2023
Q1 		$1.4M Hold
6,979
– – 0.03% 337
2022
Q4 		$1.66M Buy
6,979
+4,040
+137% +$862K 0.04% 319
2022
Q3 		$588K Hold
2,939
– – 0.01% 419
2022
Q2 		$429K Hold
2,939
– – 0.01% 444
2022
Q1 		$480K Hold
2,939
– – 0.01% 460
2021
Q4 		$498K Sell
2,939
-418
-12% -$77.7K 0.01% 464
2021
Q3 		$634K Hold
3,357
– – 0.01% 457
2021
Q2 		$569K Hold
3,357
– – 0.01% 468
2021
Q1 		$474K Hold
3,357
– – 0.01% 470
2020
Q4 		$436K Sell
3,357
-3,918
-54% -$523K 0.01% 451
2020
Q3 		$1.06M Hold
7,275
– – 0.02% 381
2020
Q2 		$1.08M Sell
7,275
-261
-3% -$35.2K 0.02% 362
2020
Q1 		$820K Hold
7,536
– – 0.03% 383
2019
Q4 		$868K Buy
7,536
+214
+3% +$21.3K 0.02% 427
2019
Q3 		$589K Hold
7,322
– – 0.01% 449
2019
Q2 		$531K Hold
7,322
– – 0.01% 464
2019
Q1 		$684K Buy
+7,322
New +$612K 0.02% 438

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dai-ichi Life Insurance Company's ALNY Position: Q1 2026 in Review

Dai-ichi Life Insurance Company reduced its Alnylam Pharmaceuticals (ALNY) stake by 5.2% in Q1 2026, selling an estimated $111K and leaving 5,930 shares worth $1.96M. The position accounts for 0.06% of the portfolio, ranked #256.

Dai-ichi Life Insurance Company first reported a position in ALNY in Q1 2019 and has held it in 27 quarters since. The position peaked at $2.49M in Q3 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Dai-ichi Life Insurance Company held 5,930 shares of Alnylam Pharmaceuticals worth $1.96M as of Q1 2026.
  • Dai-ichi Life Insurance Company sold 325 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $111K.
  • Alnylam Pharmaceuticals made up 0.06% of Dai-ichi Life Insurance Company's portfolio in Q1 2026, its #256 holding.
  • Dai-ichi Life Insurance Company first reported a position in Alnylam Pharmaceuticals in Q1 2019 and has held it in 27 quarters since.
  • Dai-ichi Life Insurance Company's Alnylam Pharmaceuticals position peaked at $2.49M in Q3 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Dai-ichi Life Insurance Company's 13F filing for Q1 2026, filed 14 May 2026.